Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer

Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.

HER2
stage iv breast cancer
direct bilirubin
epidermal growth factor
oophorectomy
  • 0 views
  • 19 Feb, 2024
4SCAR-T Therapy Post CD19-targeted Immunotherapy

This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells (4SCAR-T) targeting CD19-negative B-ALL that express alternative surface antigens such as CD22, CD10, CD20, CD38, and CD123, as many patients relapse after anti-CD19 immunotherapy. Clinical response and optiminzation of a standardized …

  • 0 views
  • 19 Feb, 2024
PHP and Immunotherapy in Metastasized UM

Melanoma of the eye (ocular/uveal melanoma) is an uncommon type of cancer that is associated with a high mortality. It usually disseminates rapidly throughout the body, most commonly to the liver and lungs. In this study a combination therapy with immunotherapy (ipilimumab with nivolumab) and chemotherapy (melphalan) will be assessed …

  • 0 views
  • 19 Feb, 2024
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients.

nasopharyngeal swab
acute respiratory syndrome (sars)
monoclonal antibodies
cancer
oximetry
  • 0 views
  • 19 Feb, 2024
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

A Phase Ib, Open-label, Single-center study to assess the safety of cancer-immunotherapy induction with Tremelimumab and Durvalumab prior to Chemoradiotherapy in the treatment of locally advanced NSCLC.

tubal ligation
follicle stimulating hormone
male sterilization
cisplatin
ebus
  • 0 views
  • 19 Feb, 2024
Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy Study

Peripheral blood mononuclear cell collection protocol for tumor immunotherapy study of UCAR-T cells

  • 0 views
  • 19 Feb, 2024
ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)

To confirm the result of previous Phase I/II and phase II clinical trials, this trial is to test the efficacy and safety of ADCTA immunotherapy plus the standard therapy in comparison with standard therapy alone in patients with recurrent GBM.

temozolomide
thromboplastin
aptt
recurrent glioblastoma
adjuvant
  • 0 views
  • 19 Feb, 2024
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the …

lung non-small cell squamous carcinoma
immunohistochemistry
stage ii lung squamous cell carcinoma ajcc v7
stage ii lung cancer ajcc v7
non-small cell lung cancer
  • 0 views
  • 19 Feb, 2024
Neoadjuvant T-VEC in High Risk Early Melanoma

Despite the recent notable advances in the treatment of advanced melanoma with application of growing immunotherapies, patterns of response and factors resulting in treatment failure are poorly understood. Moreover, the application of these therapeutics has been limited in the neoadjuvant setting, particularly in earlier stage disease, even though this strategy …

aptt
tubal ligation
platelet count
neutrophil count
karnofsky performance status
  • 0 views
  • 19 Feb, 2024
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Open-label, multicenter, dose titration and expansion three-arm trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of W_pro1 cancer vaccine (W_pro1) in patients with metastatic castration resistant prostate cancer (mCRPC) W_pro1 in combination with goserelin acetate with or without cemiplimab, in patients with high-risk, localized prostate cancer (LPC)

squamous cell carcinoma of the skin
enzalutamide
luteinising hormone
urinary tract infection
cancer vaccine
  • 2 views
  • 19 Feb, 2024